Michelle Brown

Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target

Jaap Verweij, A. van Oosterom, Jean‐Yves Blay et al. · European Journal of Cancer · 2003 · 403 citations

Medicine, Oncology, Gastrointestinal Oncology +12

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg

John Zalcberg, Jaap Verweij, Paolo G. Casali et al. · European Journal of Cancer · 2005 · 374 citations

Medicine, Oncology, Pharmacotherapy +11

Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials Group Study

M. van Glabbeke, Jaap Verweij, Paolo G. Casali et al. · Journal of Clinical Oncology · 2005 · 279 citations

Medicine, Oncology, Pharmacology +14

BNIP3 acts as transcriptional repressor of death receptor-5 expression and prevents TRAIL-induced cell death in gliomas

Teralee Burton, Elizabeth S. Henson, Meghan B. Azad et al. · Cell Death and Disease · 2013 · 36 citations · Full text

Life Sciences, Oncology, Pharmacology +17

Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression

Sekar Ashok Kumar, Xiaojie Hu, Michelle Brown et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2009 · 15 citations

Life Sciences, Cancer Biology, Cell Biology +16